You are here

Two new Board of Director appointments to liquid biopsy company Clinical Genomics

BRIDGEWATER, N.J., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Clinical Genomics, a leading provider of cancer testing solutions and liquid biopsy testing, today announced two appointments to the company’s Board of Directors:  Mary Padbury as Chairman and Katherine Bach Kalin as a member. Ms. Padbury has performed intellectual property work for Australian and multinational companies in a variety of technology areas and has extensive international, legal, and governance experience. Ms. Kalin joins the Board with over 25 years of experience as a senior executive in the healthcare and professional services industries, with multi-disciplinary expertise across diagnostics, medical devices, and pharmaceuticals. Her international work experience includes appointments in Asia, Europe and North America.

“We are pleased to welcome Mary as incoming Chair of our Board of Directors. She brings to our company a deep understanding of how to effectively commercialize new healthcare technologies,” said Lawrence LaPointe, Ph.D., CEO of Clinical Genomics. “Mary will be a vital asset to our Board and will provide valuable leadership to the organization. I would also like to thank Max Mawhinney for his many years of service as Chairman of Clinical Genomics. We look forward to his continued guidance and leadership as a member of our Board of Directors. We are also extremely fortunate to have Katherine, with her extensive global experience and expertise in the healthcare industry, as a member of our Board as we continue to carry out our mission.”

Ms. Kalin stated, “I am excited to join Clinical Genomics and do my part to help the company achieve its mission of harnessing breakthrough science to create innovative healthcare products that improve patient outcomes by detecting cancer earlier.”

“I have tremendous respect for my fellow Board members and the Clinical Genomics management team, and I look forward to working with them,” added Ms. Padbury.

Prior to retiring and joining Clinical Genomics, Ms. Padbury was a Partner and Vice Chairman of Ashurst, a global commercial law firm, and served as Chairman of Ashurst Australia for eight years before the firm’s full merger with Ashurst LLP in 2013. Ms. Padbury worked with Bristows, a UK full-service commercial law firm known mainly for its technology and intellectual property work. She currently serves as Chairman of the Board for Trans-Tasman IP Attorneys and is a member of the Board for the Macfarlane Burnet Institute for Medical Research and Public Health Ltd., Commonwealth Bank of Australia, and Victorian Legal Admissions Committee.

Ms. Padbury earned a BA LLB (Hons) from the Melbourne Law School and is a graduate of the Australian Institute of Company Directors.

Prior to joining Clinical Genomics, Ms. Kalin led corporate strategy at Celgene, a global biopharmaceutical company, for five years. Kalin held leadership roles in marketing, sales, strategy and new business development at Johnson & Johnson during the period from 2002 to 2011. Prior to J&J, Ms. Kalin served as a Partner at McKinsey and Company, a global management consulting firm, where she negotiated and led consulting assignments in global healthcare, operating as a strategic advisor to senior executives. She was a Manager in Corporate Finance at Nomura International in the United Kingdom and Japan before joining McKinsey. She also served as the President of the Board of Education for Summit, New Jersey for the 2015-16 school year.

Ms. Kalin received a BA (Hons) in French from Durham University, UK, and an MBA with distinction from Harvard Business School.

About Clinical Genomics
Clinical Genomics is dedicated to improving patient outcomes through early detection of colorectal cancer. Clinical Genomics products span the full spectrum of colorectal cancer testing, including InSure® FIT™, a fecal immunochemical test for screening in healthy adults, to COLVERA™, a proprietary blood test identifying circulating tumor DNA in patient’s post-treatment for early detection of recurrence and residual disease. Clinical Genomics is committed to developing and delivering solutions that provide physicians and their patients with information to help guide earlier and better treatment decisions in cancer care management. Clinical Genomics continues to apply its proprietary innovation in molecular pathology to commercialize other diagnostic tools in other cancer types.

For more information, please visit www.clinicalgenomics.com.

Contacts:

CLINICAL GENOMICS

Patty Jenkins, Clinical Genomics: (412) 980-1149

Tuesday, October 16, 2018 - 08:30